Camzyos (mavacamten) is a medication used to treat hypertrophic cardiomyopathy (HCM) by targeting the underlying mechanics of the heart muscle.
How does Camzyos work in the heart?
Camzyos acts as a cardiac myosin inhibitor. In HCM, the heart muscle, particularly the left ventricle, becomes abnormally thick. This thickening can stiffen the heart and obstruct blood flow, leading to symptoms like shortness of breath and chest pain. Cardiac myosin is a protein responsible for muscle contraction. Camzyos binds to cardiac myosin, reducing its ability to interact with actin, another protein involved in muscle contraction. This selective inhibition decreases the excessive force generated by the heart muscle, thereby reducing the contraction of the left ventricle and improving its ability to fill with blood [1].
What is the difference between Camzyos and other HCM treatments?
Unlike treatments that manage HCM symptoms, such as beta-blockers or calcium channel blockers, Camzyos addresses the disease mechanism directly [2]. These older medications aim to slow the heart rate or reduce blood pressure, but they do not alter the underlying hypercontractility of the heart muscle. Camzyos, by inhibiting cardiac myosin, targets this fundamental issue.
When can patients expect to see results from Camzyos?
Clinical trials have shown that Camzyos can lead to significant improvements in exercise capacity and reductions in HCM symptoms within weeks of starting treatment. For instance, the VALOR-HCM study demonstrated improvements in the 6-minute walk distance and reductions in New York Heart Association (NYHA) functional class for patients treated with mavacamten compared to placebo [3].
What are the potential risks or side effects of taking Camzyos?
A primary concern with Camzyos is the risk of reducing the heart's pumping function too much, leading to a condition called left ventricular ejection fraction (LVEF) reduction [1]. To manage this risk, regular monitoring of LVEF through echocardiograms is required during treatment. Other reported side effects include dizziness, syncope, and chest pain [4].
Are there any special considerations for taking Camzyos?
Camzyos is associated with potential drug interactions, particularly with medications that inhibit or induce CYP2C19, an enzyme involved in drug metabolism. Co-administration with strong CYP2C19 inhibitors can increase Camzyos exposure, potentially increasing the risk of LVEF reduction [1].
How is Camzyos prescribed and monitored?
Treatment with Camzyos typically begins with a low dose, which is then adjusted based on the patient's LVEF and symptoms. Frequent echocardiographic assessments are crucial to ensure the dose is safe and effective [1].
Sources
1. https://www.drugpatentwatch.com/drugs/camzyos-mavacamten-001
2. https://www.drugpatentwatch.com/news/beta-blockers-vs-mavacamten-for-hypertrophic-cardiomyopathy
3. https://www.drugpatentwatch.com/news/valor-hcm-trial-results-mavacamten-shows-promise
4. https://www.drugpatentwatch.com/drugs/camzyos-mavacamten-001/side-effects